The assessment of RB1 and TP53 mutational status on cfDNA as well as the test of neuron-specific enolase (NSE) levels in plasma at the time of progression could be taken into account to unravel a potential SCLC transformation [86]. This evidence concerns the gene RB1 and small cell lung carcinoma.